XTL Biopharmaceuticals announces extraordinary general meeting of shareholders
XTLB•
XTLB•XTL Biopharmaceuticals will hold an extraordinary shareholder meeting on December 28, 2026, to consider a private placement of up to $1 million, a possible name change to Psyga and other proposals.
Shareholders will consider a private placement of up to $1 million involving investors including director Alexander Rabinovich, and a proposed name change to Psyga or a similar name. The agenda also includes Yaron Kopel’s proposed CEO engagement terms, including options to purchase up to 550,000 American Depositary Shares, each representing 400 ordinary shares.
Other proposals cover Guy Rosen’s appointment as an external director for three years, his compensation and a conditional grant of options to purchase 1 million ordinary shares. The meeting is scheduled for December 28, 2026, at the company’s attorneys’ offices in Tel Aviv.